Cervical cancer vaccines jointly win UK Prix Galien
This article was originally published in Scrip
Executive Summary
The UK Prix Galien Medal for Innovation has been awarded jointly to the two marketed cervical cancer vaccines,Sanofi-Pasteur MSD's Gardasil andGlaxoSmithKline's Cervarix. Other products highly commended for their innovation werePfizer's Champix andMS&D's Januvia, and commended products were Roche's Herceptin and MabThera, and Wyeth's Tygacil. The Prix Galien for orphan drug development was won by Novartis for Exjade, which is used to treat chronic iron overload in patients with thalassaemias. Commended orphans were GlaxoSmithKline's Atriance, Novartis's Tasigna, Bristol-Myers Squibb's Sprycel, Wyeth's Torisel and Encysive's Thelin. The judging panel was chaired by Sir Michael Rawlins, the chairman of the National Institute for health and Clinical Excellence.